Survival Benefit of Tamoxifen in Estrogen Receptor-Negative and Progesterone Receptor-Positive Low Grade Breast Cancer Patients / 한국유방암학회지
Journal of Breast Cancer
; : 288-295, 2012.
Artigo
em Inglês
| WPRIM (Pacífico Ocidental)
| ID: wpr-200193
Biblioteca responsável:
WPRO
ABSTRACT
PURPOSE:
This study aimed to analyze the efficacy and prognostic significance of adjuvant tamoxifen in breast cancer patients with various hormone receptor statuses.METHODS:
Typically, 1,260 female breast cancer patients were recruited in this study. The correlation between estrogen receptor (ER)/progesterone receptor (PR) phenotypes and clinical characteristics was investigated, and the survival rate was assessed after 5-year follow-up.RESULTS:
The 5-year overall survival (85%) was better in women under the age of 50 years. Patients with ER+/PR+ tumors had a better 5-year survival rate (94%); those with ER-/PR- tumors experienced the worst outcome (74% survival rate); whereas single-positive cases were in between. In 97 out of 128 patients with ER-/PR+ tumors, tamoxifen was given as adjuvant hormonal therapy, and it increased the survival benefit in the lower grade group in terms of overall survival and disease-free survival (p=0.01 and p=0.03, respectively).CONCLUSION:
For high-grade tumors with ER-/PR+, adjuvant tamoxifen therapy may have no survival benefit, whereas for the patients with low-grade ER-/PR+ tumors, adjuvant tamoxifen therapy is highly suggestive.
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Assunto principal:
Fenótipo
/
Progesterona
/
Tamoxifeno
/
Mama
/
Neoplasias da Mama
/
Receptores de Progesterona
/
Taxa de Sobrevida
/
Intervalo Livre de Doença
/
Estrogênios
Tipo de estudo:
Estudo prognóstico
Limite:
Feminino
/
Humanos
Idioma:
Inglês
Revista:
Journal of Breast Cancer
Ano de publicação:
2012
Tipo de documento:
Artigo